Pharma
Stay up to date with the latest pharma news and analysis from across the global pharmaceutical and biopharmaceutical industry. From drug approvals and pipeline updates to M&A activity and regulatory developments, our coverage tracks the trends shaping the future of medicine.
The pharmaceutical industry is moving through one of its most transformative periods. GLP-1 receptor agonists and oral obesity drugs are rewriting the metabolic disease market. Artificial intelligence is accelerating pharmaceutical R&D. A wave of patent expiries is reshaping the competitive landscape. Staying informed has never been more important.
Life Science Daily News covers every stage of the drug development lifecycle: preclinical research, clinical trials across Phase 1, Phase 2, and Phase 3, FDA and EMA regulatory decisions, drug approvals, commercial launch, and post-marketing surveillance. Reporting spans biologics, small molecule therapies, branded pharmaceuticals, biosimilars, and the generic drug market across oncology, obesity and metabolic disease, rare diseases and orphan drug development, autoimmune disorders, neuroscience, cardiovascular disease, and infectious disease.
CRISPR and gene therapy, CAR-T cell therapy, antibody-drug conjugates, radiopharmaceuticals, precision medicine, and blockbuster drugs facing patent cliff and intellectual property exposure are all key topics. Pharma and biopharma M&A activity, licensing deals, biotech acquisitions, venture capital funding, IPO activity, pharmaceutical manufacturing, CDMO partnerships, and supply chain developments round out the commercial picture.
Regulatory and policy coverage includes accelerated approval, breakthrough therapy and fast track designations, PDUFA dates, pharmacovigilance, drug safety, market access, drug pricing, reimbursement, and health economics and outcomes research (HEOR). Sources include clinical trial data, peer-reviewed research, regulatory filings, medical conference presentations, and expert commentary.
Explore the latest pharma articles on this page. Subscribe for updates, or contribute your own expertise through our Explorer content programme for credentialed industry professionals.
Don’t wait for the media to pick up your story. Be the media.
